

DEPARTMENT OF

HEALTH AND HUMAN SERVICES

DIVISION OF HEALTH CARE FINANCING AND POLICY Helping people. It's who we are and what we do.



Stade Weeks, JD MPH Administrator

Drug Utilization Review

Board Meeting Minutes

Date of Meeting: Thursday, January 18, 2024

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board

Agenda Item	Record			Notes
1. Call to Order and Roll Call	It was announced the meeting is being record	ed.		DHCFP Staff Present were as follows:
	Chairperson Jennifer Wheeler called the meet p.m. on January 18, 2024. Chairperson Wheeler took the roll.	ing to orde	r at 1:39	 Griffin, Karen, Senior Deputy Attorney General (SDAG) Duncan, Keiko, PharmD, Medicaid Pharmacy Director Clemons, Roshanda, MD, Medical
		Present	Absent	 Director Chattin, Amy, PhD, Medicaid Pharmacy Chief
	• Jennifer Wheeler, Pharm.D., Chair	\boxtimes		Pharmacy Chief
	• Netochi Adeolokun, Pharm.D., Vice-Chair	\boxtimes		Magellan Rx Staff Present were as
	Crystal Castaneda, MD	\boxtimes		follows:
	• Jessica Cate, Pharm.D.		\boxtimes	• Mishra, Raj, Pharm.D., Clinical Account
	• Dave England, Pharm.D.		\boxtimes	Manager
	• Brain Le, DO	\boxtimes		Kim, James, Pharm.D., Dir. Clinical
	Rebecca Sparks, PA-C		\boxtimes	Account Services
	• Jim Tran, Pharm.D.	\boxtimes		Martinez, Chris, Sr. Business Analyst
				Managed Care Organization representatives present were as follows:

					 Lim, Luke, Pharm.D., Anthem Bitton, Ryan, Pharm.D., Health Plan of Nevada Beranek, Thomas, Pharm.D., Silver Summit Health Plan Tran, Jimmy, Pharm.D., Molina Healthcare The public attendee list is included as Attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured.
2. General Public Comment	Telephonic and web comment was called for, were opened.	and th	e phor	ie lines	
	No public comment was provided.				
3. Administrative	· · ·				
a. For Possible Action: Review	Vice-Chair Netochi Adeolokun moved to appro	ve the	minute	es as	
and Approve Meeting Minutes from October 19,	presented, and Board Member Brain Le secon	ded th	ne moti	on.	
2023.	A vote was taken, and the results were as follo	ws fro	m men	nbers in	
	attendance (in favor, against, and abstentions	where	e applio	cable):	
		Yes	No	Abst.	
	Jennifer Wheeler, Pharm.D., Chair	\boxtimes			
	Netochi Adeolokun, Pharm.D., Vice-Chair	\boxtimes			
	Crystal Castaneda, MD	\boxtimes			
	Jessica Cate, Pharm.D.			\boxtimes	
	• Dave England, Pharm.D.			\boxtimes	
	Brain Le, DO	\boxtimes			

	Rebecca Sparks, PA-C	
	Jim Tran, Pharm.D.	
b. Status Update by DHCFP	Medicaid Pharmacy Director, Dr. Keiko Duncan provided an	
	announcement.	
	 DHCFP is currently still building out the pharmacy unit. 	
	 Amy Chattin is the new Chief of Pharmacy Services. 	
	Ellen Flowers has been promoted.	
	There is still currently an opening that needs to be filled.	
4. Clinical Presentations		
a. For Possible Action:		
Discussion and possible adoption of prior		
authorization criteria and/or		
quantity limits for Saphnelo .		
i. Public comment on	Telephonic and web comment was called for, and the phone lines	
proposed clinical prior	were opened.	
authorization criteria.		
	No public comment was provided.	
ii. Presentation of	Dr. Raj Mishra provided the clinical background and indications for	
utilization and clinical	Saphnelo.	
information.	Dr. Mishra reviewed the proposed criteria presented in the binder	
	and discussed the utilization of Saphnelo.	
	• Dr. Luke Lim with Anthem, approved of the proposed criteria and	
	utilization presented.	
	• Dr. Ryan Bitton with Health Plan of Nevada, approved of the	
	proposed criteria and utilization presented.	
	• Dr. Thomas Beranek with Silver Summit Health Plan, approved of	
	the proposed criteria and utilization presented.	
	Dr. Jimmy Tran with Molina Healthcare, approved of the	
	proposed criteria and utilization presented.	

 iii. Discussion by Board and review of utilization data. iv. Proposed adoption of updated prior authorization criteria. 	Chairperson Wheeler asked for comments from No comments were made. Board Member Le moved to approve the criter Magellan and Board Member Jim Tran seconde A vote was taken, and the results were as follow attendance (in favor, against, and abstentions	ia as p ed the ws froi	resent motion m merr	ed by n. nbers in	
	 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice-Chair Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes	No	Abst.	
 b. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Tavneos. i. <u>Public comment</u> on proposed clinical prior authorization criteria. 	Telephonic and web comment was called for, a were opened. No public comment was provided.	and the	e phon	e lines	
ii. Presentation of utilization and clinical information.	Dr. Mishra provided the clinical background an Tavneos. Dr. Mishra reviewed the proposed criteria pres and discussed the utilization for Tavneos.				

iii. Discussion by Bo review of utiliza	tion	da, approved alth Plan, app esented. oproved of th	of the roved o e prop	proposed of the osed
data. iv. Proposed adopt updated prior	Magellan, and Board Member Tran sec			sented by
authorization cr	A vote was taken, and the results were	A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):		
	 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	-Chair -Chair	No	Abst.
c. For Possible Action: Discussion and possib adoption of prior authorization criteria quantity limits for Up	and/or			

i. <u>Public comment</u> of proposed clinical authorization crit	prior were opened.
ii. Presentation of utilization and clin information.	Dr. Mishra provided the clinical background and indications for uplizna. Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Uplizna. • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.
iii. Discussion by Board review of utilization	
iv. Proposed adoption updated prior authorization criter	Magellan with the addition of not receiving a live vaccine 4 weeks

	YesNoAbst.Jennifer Wheeler, Pharm.D., ChairIINetochi Adeolokun, Pharm.D., Vice-ChairIICrystal Castaneda, MDIIJessica Cate, Pharm.D.IIJessica Cate, Pharm.D.IIDave England, Pharm.D.IIBrain Le, DOIIRebecca Sparks, PA-CIIJim Tran, Pharm.D.II	
 d. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Voxzogo. 		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. Public comment was provided by Rick Kegler.	
ii. Presentation of utilization and clinical information.	 Dr. Mishra discussed the indications for Voxzogo. Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Voxzogo. Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. 	

	• Dr. Tran with Molina Healthcare, approve criteria and utilization presented.	d of th	e prop	osed		
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments fro Comment was made by Vice-Chair Adeolokun		Board	Members.		
iv. Proposed adoption of updated prior authorization criteria.	Vice-Chair Adeolokun moved to approve the o Magellan, and Board Member Le seconded th A vote was taken, and the results were as follo attendance (in favor, against, and abstentions	e moti ws fro	on. m men	nbers in		
	 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice-Chair Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes ⊠ ⊠ ⊠ □ □ ⊠ ⊠	No	Abst.		
e. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Narcolepsy Agents.					 	
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, were opened.	and th	e phon	e lines		

	Public comment was provided by Dr. Charlotte Wincott with Axsome Therapeutics. Public comment was provided by Michael Faithe, Payer, Value & Outcomes at Jazz Pharmaceuticals.
Presentation of utilization and clinical information.	 Dr. Mishra discussed the indications for Narcolepsy agents. Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Narcolepsy agents. Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.
Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.
Proposed adoption of updated prior authorization criteria.	Board Member Castaneda moved to approve the criteria as presented by Magellan and Board Member Tran seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):
	YesNoAbst.Jennifer Wheeler, Pharm.D., ChairImage: Comparison of the system of the

	 Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	
 f. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Anti- Hepatitis Agents. 		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.	
ii. Presentation of utilization and clinical information.	 Dr. Mishra discussed the indications for Anti-Hepatitis Agents. Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Anti-Hepatitis Agents. Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No Comments were made.	

iv. Proposed adoption of updated prior authorization criteria.	Board Member Castaneda moved to approve to presented by Magellan and Board Member Tra- motion. A vote was taken, and the results were as follo attendance (in favor, against, and abstentions	an secon ws from	ded t mem	he: bers in	
	 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice-Chair Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 		No	Abst.	
v. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Incretin Mimetics.					
vi. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, were opened. No public comment was provided.	and the p	phon	e lines	
vii. Presentation of utilization and clinical information.	 Dr. Mishra discussed the indications for Incret Dr. Mishra reviewed the proposed criteria pre and discussed the utilization for Incretin Mime Dr. Lim with Anthem, approved of the pro utilization presented. 	sented ir tics.	n the		

		 Dr. Bitton with Health Plan of Nevada, app criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved criteria and utilization presented. 	n, app I.	roved o	of the
v	viii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from Comment was made by Vice-Chair Adeolokun.	n the	Board I	Vembers.
	roposed adoption of updated rior authorization criteria.	Board Member Castaneda moved to approve the criteria as presented by Magellan with the removal of the word adult and substituting it with FDA approved age and Vice-Chair Adeolokun seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):			
			Yes	No	Abst.
		 Jennifer Wheeler, Pharm.D., Chair 	\boxtimes		
		Netochi Adeolokun, Pharm.D., Vice-Chair	\boxtimes		
		 Crystal Castaneda, MD 	\boxtimes		
		 Jessica Cate, Pharm.D. 			\boxtimes
		• Dave England, Pharm.D.			\boxtimes
		Brain Le, DO	\boxtimes		
		Rebecca Sparks, PA-C			\boxtimes
		• Jim Tran, Pharm.D.	\boxtimes		
	 Opioid Reports: i. Opioid Trends ii. Count of Claims iii. Med Trend 	 Dr. Mishra presented opioid utilization rep Dr. Lim presented opioid utilization report Dr. Bitton presented opioid utilization rep Dr. Beranek presented opioid utilization rep 	s. orts.		

·		
iv. Top Members	Dr. Tran presented opioid utilization reports.	
v. Top Prescribers	Chairperson Wheeler acked for comments from Beard Members	
vi. Top Pharmacy	Chairperson Wheeler asked for comments from Board Members	
	regarding Opioid Reports. The Board discussed utilization and trends.	
	No additional action taken or motions for investigative referrals.	
b. Standard DUR Reports:	Dr. Mishra presented Standard DUR Reports	
i. Top 10 Classes by	Dr. Lim presented Standard DUR Reports.	
Amount Paid	 Dr. Bitton presented Standard DUR Reports 	
ii. Top 10 Classes by Claim	 Dr. Beranek presented Standard DUR Reports 	
Count	• Dr. Tran presented Standard DUR Reports.	
iii. Quarterly ProDUR Paid		
Claims Saving Report		
iv. Retro DUR Initiatives		
6. Closing Discussion		
a. Public Comment	Telephonic and web comment was called for, and the phone lines	
	were opened.	
	No public comment was provided.	
b. For Possible Action: Date	Chairperson Wheeler stated the next meeting is scheduled for April	
and location of the next	18, 2024.	
meeting.		
inceeding.	Location: Hilton Garden Inn Reno	
	Meeting adjourned at 3:09 pm	
	meeting aujourned at 3.03 pm	

Attachment A – Members of the Public in Attendance

Linda	Nunes	Jeana	Colabianchi	Karen	Ou	Joe	Payne
Lori	Howarth	Sara	Stolfus	Rodney	Cobb	Uche	Mordi
Jason	Douglas	Christine	Dube	Lisa	Ashton	Robert	Peace
Bethany	Holderread	Rick	Kegler	Amy	Hale	Jason	Douglas
John	Breen	Aaron	Girvin	Justen	Caleca	Eric	Perry

Michael	Pazirandeh	Gary	Parenteau	Sean	Mohebbi
Michael	Faithe	Christian	Johnson	Lea	Case
Christina	Hartmann	charlotte	Wincott	Bernard	Kim
Todd	Dickerson	Morgan	Biaselli	Melissa	D
Ken	Liu	Silky	Beaty	Joe	Payne

Attachment B – Submitted Written Comment